Dr. Mylari obtained his Ph.D in organic chemistry from Indiana University in 1966. After a year of post-doctoral research, he joined Pfizer in 1967. Over the next 34 years of continuous service at Pfizer, Dr. Mylari worked on a number of successful projects spanning both animal health and human health targets. These targets included projects in synthetic antibacterials, synthetic antiprotozoals, fermentation-derived antibacterials, semi-synthetic antimirobials, anti-inflammatory/analgesic agents, antihypertnsives, and therapeutic agents for diabetic complications. Dr. Mylari played a critical role in the successful commercialization of the animal health antibiotic, salinomycin, and discovery/development efforts leading to one of the potent aldose reductase inhibitors, zopolrestat (Phase III), for diabetic complications. Developing and executing effective strategies for protection of intellectual property was a hallmark of his career at Pfizer. He is experienced in almost all facets of drug discovery and development. Dr. Mylari has published extensively in major journals (62 publications, including journal publications and presentations). In addition, he is an inventor/co-inventor on 51 US patents with more US patents still pending.

Dr. Mylari retired from Pfizer in January 2001; and is now an independent R&D consultant with several clients, including Pfizer Inc. He is a member of the scientific advisory board of Millennium Pharmaceuticals.